Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia

NCT02180724 is registered in ClinicalTrials.gov with Acerta Pharma BV as lead sponsor.

NCT NCT02180724
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02180724 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia
Lead sponsor
Acerta Pharma BV
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 11, 2014
Completion date
December 31, 2026
Enrollment
107 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

waldenström macroglobulinemia (wm)